OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy – GlobeNewswire (press release)
|
OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
GlobeNewswire (press release) NANTES, France, Oct. 19, 2017 (GLOBE NEWSWIRE) — OSE Immunotherapeutics SA (ISIN: FR0012127173) (Mnémo:OSE), today announces the positive results of two preclinical studies evaluating FR104, an anti-antagonist antibody of CD28, a receptor … |
